Related Experiment Video
Updated: May 31, 2026

Designing Porous Silicon Films as Carriers of Nerve Growth Factor
Published on: January 25, 2019
Emergence of the silicon human and network targeting drugs
Alexey Kolodkin1, Fred C Boogerd, Nick Plant
1Molecular Cell Physiology, VU University Amsterdam, de Boelelaan 1085, NL-1081 HV Amsterdam, The Netherlands.
Abstract:
The development of disease may be characterized as a pathological shift of homeostasis; the main goal of contemporary drug treatment is, therefore, to return the pathological homeostasis back to the normal physiological range. From the view point of systems biology, homeostasis emerges from the interactions within the network of biomolecules (e.g. DNA, mRNA, proteins), and, hence, understanding how drugs impact upon the entire network should improve their efficacy at returning the network (body) to physiological homeostasis. Large, mechanism-based computer models, such as the anticipated human whole body models (silicon or virtual human), may help in the development of such network-targeting drugs. Using the philosophical concept of weak and strong emergence, we shall here take a more general look at the paradigm of network-targeting drugs, and propose our approaches to scale the strength of strong emergence. We apply these approaches to several biological examples and demonstrate their utility to reveal principles of bio-modeling. We discuss this in the perspective of building the silicon human.
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Drug Discovery: Overview
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

